
    
      This is a non-controlled, open-label, flexible-dose, international multi-centre extension
      study. The patient population consists of male and female patients with schizophrenia, who
      have completed open-label bifeprunox studies 10206 or 10265, and require continued treatment
      with bifeprunox, other treatments not being feasible as judged by the investigator.
    
  